5 terminated. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Terminated 5 |
Follow Adrenocortical Hyperfunction: new trials by email Literature Review of Adrenocortical Hyperfunction trials Research Report on Adrenocortical Hyperfunction
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of ATR-101 for the Treatment of Endogenous Cushing's Syndrome ATR-101, Placebo - Cushing Syndrome | Phase 2 | Terminated | Millendo Therapeutics US, Inc. | 4 | 2017-04-13 | 2021-03-02 |
| Treatment of Cushing's Disease With R-roscovitine R-roscovitine - Cushings Disease | Phase 2 | Terminated | Shlomo Melmed, MD | 4 | 2014-05-01 | 2021-11-04 |
| Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease Pasireotide with or without cabergoline - Cushings Disease | Phase 2 | Terminated | Novartis Pharmaceuticals | 68 | 2014-03-06 | 2020-09-18 |
| Study of Adrenalectomy Versus Observation for Subclinical Hypercortisolism Adrenalectomy, Observation - Subclinical Hypercortisolism, Cushing Syndrome | Phase 2 | Terminated | National Cancer Institute (NCI) | 4 | 2013-11-27 | 2018-06-14 |
| Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion Mifepristone - Cushing's Syndrome | Phase 2 | Terminated | HRA Pharma | 18 | 2007-05-15 | 2019-10-11 |
Cushing Syndrome (3) · ACTH Syndrome, Ectopic (1) · Adrenal Gland Neoplasms (1) · Adrenal incidentaloma (1) · Diabetes Mellitus (1) · Hypercholesterolemia (1) · Hypertension (1) · Obesity (1) · Osteoporosis (1) · Pituitary ACTH Hypersecretion (1) · Pituitary Neoplasms (1)
Adrenal Gland Diseases (5) · Endocrine System Diseases (5) · Neoplasms (3) · Endocrine Gland Neoplasms (2) · Neoplasms by Site (2) · Body Weight (1) · Bone Diseases (1) · Bone Diseases, Metabolic (1) · Brain Diseases (1) · Brain Neoplasms (1) · Cardiovascular Diseases (1) · Central Nervous System Diseases (1) · Central Nervous System Neoplasms (1) · Dyslipidemias (1)
Adrenalectomy (1) · Cabergoline (1) · Mifepristone (1) · N-(2,6-bis(1-methylethyl)phenyl)-N'-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride (1) · Observation (1) · Roscovitine (1) · pasireotide (1)
HRA Pharma (1) · Millendo Therapeutics US, Inc. (1) · National Cancer Institute (NCI) (1) · Novartis Pharmaceuticals (1) · Shlomo Melmed, MD (1)
United States (5) · France (2) · Germany (2) · Italy (2) · Netherlands (2) · Argentina (1) · Belgium (1) · Brazil (1) · Colombia (1) · Greece (1) · Hungary (1) · India (1) · Malaysia (1) · Mexico (1) · Spain (1)
Dhaval T Patel, M.D. (1) · James Findling, MD (1) · Lynnette K Nieman, M.D. (1) · Ning-Ai Liu, MD, PhD (1) · Shlomo Melmed, MD (1)
R21DK103198 (1)